Form 4: United Therapeutics COO Exercises Options and Sells Shares Under 10b5-1 Plan

United Therapeutics' President and COO, Michael Benkowitz, executed stock options and sold shares on December 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of the company's common stock on December 9, 2024.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan established on August 7, 2024.
• The transactions involved multiple trades at varying prices, with weighted average prices reported for each sale.
• The shares were held indirectly through a trust where Mr. Benkowitz is a co-trustee and beneficiary, and another trust where his family members are beneficiaries.
• A total of 15,000 stock options were exercised at prices of $102.11 and $111.
• A total of 9,478 shares were sold at prices ranging from $364.87 to $372.39.

Sentiment

Score: 5

Explanation: The document reflects routine transactions by an executive under a pre-arranged plan. It is neither particularly positive nor negative for the company's outlook.

Positives

• The transactions were conducted under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to avoid accusations of insider trading.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• The market may react negatively to the sale of shares by a company executive, even if it is part of a pre-planned trading strategy.
• There is a risk of misinterpretation of the transactions by investors, potentially leading to volatility in the stock price.

Industry Context

This type of transaction is common for executives of publicly traded companies, especially when using pre-arranged trading plans to manage their personal finances and avoid insider trading concerns. It is a routine disclosure and does not necessarily indicate a change in the company's outlook.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a standard practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors, such as Amgen, Gilead Sciences, and Biogen.
• These companies often have similar disclosures related to executive stock option exercises and share sales.
• The reported prices for the share sales are within the typical range for market transactions, and the weighted average price reporting is consistent with SEC requirements for such disclosures.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as the sale of shares by an executive could be perceived negatively by some investors.
• The impact on other stakeholders such as employees, customers, and suppliers is likely to be minimal.

Key Dates

Keywords

insider trading, stock options, share sale, Rule 10b5-1, executive compensation, United Therapeutics, UTHR, Michael Benkowitz